TX-HITRUST
6.10.2021 15:02:10 CEST | Business Wire | Press release
HITRUST® announced today a major expansion of its assessment portfolio to raise the quality and efficiency of assurances across the spectrum of information assurance needs. HITRUST also is unveiling a new evolutionary approach to streamline the exchange and consumption of assessment results across the ecosystem of relying parties.
HITRUST CSF Certification is the most reliable information assurance report on the market and made possible by the transparency and consistency in the selection of controls, and in the scoring, and validation of controls by both qualified third-party assessors and the HITRUST Assurance and Quality teams. The assurance process is rigorous by design to ensure a high level of assurance in the results provided. However, there are many situations where a moderate or low level of assurance is warranted. Organizations are seeking a broader range of assessment options that require less effort and time to perform while still providing a commensurate level of reliability for moderate- to lower-risk scenarios.
To meet the market needs for varying levels of assurance with higher reliability, HITRUST is adding two new assessment offerings. Like the HITRUST CSF Validated Assessment, these new offerings will aid in understanding control effectiveness as well as cyber preparedness and resilience. With the two new additions, the HITRUST assessment portfolio will include:
- The Basic Current State (bC) Assessment is a “good hygiene” assessment and offers higher reliability than self-assessments and questionnaires by utilizing the HITRUST Assurance Intelligence Engine™ (AI Engine) to identify errors, omissions, and deceit.
- The Implemented One-Year (i1) Validated Assessment is a “best practices” assessment and recommended for situations that present moderate risk or where a baseline risk assessment is needed. The i1 is designed to provide higher levels of transparency, integrity, and reliability over existing moderate assurance reports, with comparable levels of time, effort, and cost. HITRUST Authorized External Assessors will validate i1 assessments.
- The industry standard HITRUST CSF Validated Assessment is a risk-based and tailorable assessment, which continues to provide the highest level of assurance for situations with greater risk exposure due to data volumes, regulatory compliance, or other risk factors. The HITRUST CSF Validated Assessment will be renamed the Risk-based, Two-Year (r2) Validated Assessment.
Until now, most low to moderate risk assessment mechanisms were either self-attested or validated against unsuitable or inconsistent control selection and limited and subjective assurance programs; which makes it difficult for relying parties to understand the control requirements and depth, breadth, and consistency of the assurance process, limiting the usefulness and reliability of the results.
“Often, organizations utilize mid-level assurance reports such as a SOC 2 report because they take less time and effort while being less costly. Unfortunately, these mid-level assurance reports lack the consistency and reliability of more comprehensive assessments like HITRUST,” said John Houston, Vice President of Information Security and Privacy at UPMC. “The HITRUST i1 Assessment fills a gap in the market for a medium assurance assessment that delivers a higher level of reliability and consistency while having a similar effort and cost to a SOC 2 report. And it can help the organization move towards full HITRUST CSF Certification—which organizations like UPMC view as the gold standard.”
While reliability is crucial for assurance, the accessibility, usability, and consumption of the results are just as important if organizations are to manage supply chain risk given evolving cyber threats. The current method of obtaining and consuming assessment results by the relying party often results in delays, inefficiencies, and misinterpretations as it is based on the exchange of PDF files that are reviewed to determine the scope, scoring, and corrective action plans before key information is often manually entered into a third-party risk management (TPRM) system.
To meet the expanding demand for effective information risk management across the supply chain, the HITRUST Results Distribution System (RDS) will enable assessed entities to deliver their HITRUST Assessment results through a secure, centralized reporting hub to relying parties, eliminating the need for exchanging PDFs and the manual review and entry into third-party systems that subsequently occurs. Recipients will be able to customize dashboards to view the results that interest them most, including scope, aggregate, or specific control scores. In addition, integration with GRC/VRM platforms will be available via API.
“For third-party risk management systems to achieve their full potential in helping organizations manage their vendor risk, assessment results need to be electronically shared and consumed,” said Jeremy Fisher, Vice President of Product at Archer. “HITRUST’s Results Distribution System is a big step in making that possible and will be a strong complement to our focus on vendor interaction through Archer Engage.”
The expansion of the HITRUST Assessment Portfolio and the addition of the RDS further extend HITRUST’s position as an innovator and leader in information risk management, compliance, and assurance. HITRUST continues to drive higher assurances and greater efficiencies into the assurance ecosystem. “HITRUST is building upon our market leadership in providing Rely-Able assurances by introducing moderate and low-level information assurance products,” said Bimal Sheth, Executive Vice President, Standards Development and Assurance Operations, HITRUST. “No other assessment or certification organization is able to meet the expanding global market need for information assessments and electronic results distribution.”
The industry standard r2 assessment (HITRUST CSF Validated Assessment) is currently available while the bC and i1 assessments will be offered to the market later this year. Any i1 or r2 assessment submitted with a reservation is backed by a service-level guarantee to deliver the assessment report within 45 days.
To Learn More:
About HITRUST®
Since it was founded in 2007, HITRUST has championed programs that safeguard sensitive information and manage information risk for organizations across all industries and throughout the third-party supply chain. In collaboration with privacy, information security, and risk management leaders from the public and private sectors, HITRUST develops, maintains, and provides broad access to its widely adopted common risk and compliance management frameworks as well as related assessment and assurance methodologies. For more information, visit www.hitrustalliance.net .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211006005249/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vonage Expands Developer Ecosystem to Accelerate the Next Era of Enterprise Digital Transformation19.2.2026 10:08:00 CET | Press release
Vonage verified Postman workspace extends reach by 40+ million developers; MCP servers and Startup Program among resources designed to further accelerate time-to-value for developers and enterprises Vonage, part of Ericsson (NASDAQ: ERIC), today announced a number of new initiatives, to further expand and enable its global developer community. By growing its developer community and tools, giving developers and enterprises access to new mobile network insights and capabilities that can be embedded into existing applications and workflows, Vonage is accelerating its strategy to transform mobile networks into a programmable platform. Putting Vonage APIs in the Hands of 40 million+ More Developers Vonage is announcing the launch of its Verified Workspace on the Postman API Network, making Vonage APIs available to the 40+ million developers who use Postman. The new, verified workspace gives Postman’s community of global developer members certified access to Vonage’s portfolio of Network API
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release
The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
